| Comparison . | Exposed Group . | DLCO (mL/min/mm Hg), Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differencea (95% CI) . | Percent Predicted DLCO, Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differenceb (95% CI) . | DLCO z Score, Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differenceb (95% CI) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Comparison Group . | ||||||||||
| HCV seropositivity | Seropositive (n = 133) | 15.1 (4.0) | −2.7 (−3.4 to −1.9) | −1.2 (−1.9 to −.4) | 78 (18) | −10 (−13 to −6) | −5 (−9 to −1) | −2.07 (1.70) | −0.78 (−1.07 to −.49) | −0.71 (−1.05 to −.37) |
| Seronegative (n = 536) | 17.7 (4.1) | P < .0001 | P = .004 | 88 (17) | P < .0001 | P = .01 | −1.29 (1.47) | P < .001 | P < .001 | |
| HCV viremia | Viremic (n = 24) | 16.6 (4.5) | 1.9 (.2–3.7) | 1.1 (−.6 to 2.7) | 86 (18) | 9 (1–17) | 6 (−2 to 15) | −1.51 (1.37) | 0.68 (−.07 to 1.43) | 0.77 (−.06 to 1.59) |
| Not viremic (n = 109) | 14.7 (3.8) | P = .03 | P = .20 | 77 (18) | P = .03 | P = .16 | −2.19 (1.74) | P = .07 | P = .07 | |
| HCV treatment status | Prior HCV treatment history (n = 61) | 14.5 (3.5) | −0.5 (−2.0 to .9) | 0.3 (−1.1 to 1.7) | 75 (17) | −3 (−10 to 4) | 1 (−6 to 8) | −2.26 (1.65) | −0.16 (−.83 to .51) | 0.21 (−.53 to .96) |
| No prior HCV treatment history (n = 48) | 15.0 (4.1) | P = .46 | P = .41 | 78 (20) | P = .39 | P = .81 | −2.10 (1.87) | P = .63 | P = .58 | |
| Exposure to interferon and/or ribavirin | Exposed to interferon/ribavirin (n = 15) | 15.7 (4.2) | 1.6 (−.5 to 3.7) | 1.8 (−.4 to 4.0) | 82 (19) | 9 (−1 to 18) | 11 (−1 to 22) | −1.75 (2.04) | 0.67 (−.30 to 1.65) | 0.69 (−.43 to 1.82) |
| Not exposed to interferon/ribavirin (n = 46) | 14.1 (3.2) | P = .12 | P = .11 | 73 (16) | P = .09 | P = .07 | −2.43 (1.49) | P = .17 | P = .22 |
| Comparison . | Exposed Group . | DLCO (mL/min/mm Hg), Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differencea (95% CI) . | Percent Predicted DLCO, Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differenceb (95% CI) . | DLCO z Score, Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differenceb (95% CI) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Comparison Group . | ||||||||||
| HCV seropositivity | Seropositive (n = 133) | 15.1 (4.0) | −2.7 (−3.4 to −1.9) | −1.2 (−1.9 to −.4) | 78 (18) | −10 (−13 to −6) | −5 (−9 to −1) | −2.07 (1.70) | −0.78 (−1.07 to −.49) | −0.71 (−1.05 to −.37) |
| Seronegative (n = 536) | 17.7 (4.1) | P < .0001 | P = .004 | 88 (17) | P < .0001 | P = .01 | −1.29 (1.47) | P < .001 | P < .001 | |
| HCV viremia | Viremic (n = 24) | 16.6 (4.5) | 1.9 (.2–3.7) | 1.1 (−.6 to 2.7) | 86 (18) | 9 (1–17) | 6 (−2 to 15) | −1.51 (1.37) | 0.68 (−.07 to 1.43) | 0.77 (−.06 to 1.59) |
| Not viremic (n = 109) | 14.7 (3.8) | P = .03 | P = .20 | 77 (18) | P = .03 | P = .16 | −2.19 (1.74) | P = .07 | P = .07 | |
| HCV treatment status | Prior HCV treatment history (n = 61) | 14.5 (3.5) | −0.5 (−2.0 to .9) | 0.3 (−1.1 to 1.7) | 75 (17) | −3 (−10 to 4) | 1 (−6 to 8) | −2.26 (1.65) | −0.16 (−.83 to .51) | 0.21 (−.53 to .96) |
| No prior HCV treatment history (n = 48) | 15.0 (4.1) | P = .46 | P = .41 | 78 (20) | P = .39 | P = .81 | −2.10 (1.87) | P = .63 | P = .58 | |
| Exposure to interferon and/or ribavirin | Exposed to interferon/ribavirin (n = 15) | 15.7 (4.2) | 1.6 (−.5 to 3.7) | 1.8 (−.4 to 4.0) | 82 (19) | 9 (−1 to 18) | 11 (−1 to 22) | −1.75 (2.04) | 0.67 (−.30 to 1.65) | 0.69 (−.43 to 1.82) |
| Not exposed to interferon/ribavirin (n = 46) | 14.1 (3.2) | P = .12 | P = .11 | 73 (16) | P = .09 | P = .07 | −2.43 (1.49) | P = .17 | P = .22 |
Estimates for which the P value is less than 0.05 are in bold. Abbreviations: CI, confidence interval; DLCO, diffusing capacity for carbon monoxide; HCV, hepatitis C virus; SD, standard deviation.
aAdjusted for age, height, education level, hemoglobin, carboxyhemoglobin, human immunodeficiency virus (HIV) infection, self-reported cigarette smoking (measured in pack-years and current smoking status), and self-reported heroin, cocaine, and cannabis use.
bAdjusted for age, education level, HIV infection, self-reported cigarette smoking (measured in pack-years and current smoking status), and self-reported heroin, cocaine, and cannabis use.
| Comparison . | Exposed Group . | DLCO (mL/min/mm Hg), Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differencea (95% CI) . | Percent Predicted DLCO, Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differenceb (95% CI) . | DLCO z Score, Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differenceb (95% CI) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Comparison Group . | ||||||||||
| HCV seropositivity | Seropositive (n = 133) | 15.1 (4.0) | −2.7 (−3.4 to −1.9) | −1.2 (−1.9 to −.4) | 78 (18) | −10 (−13 to −6) | −5 (−9 to −1) | −2.07 (1.70) | −0.78 (−1.07 to −.49) | −0.71 (−1.05 to −.37) |
| Seronegative (n = 536) | 17.7 (4.1) | P < .0001 | P = .004 | 88 (17) | P < .0001 | P = .01 | −1.29 (1.47) | P < .001 | P < .001 | |
| HCV viremia | Viremic (n = 24) | 16.6 (4.5) | 1.9 (.2–3.7) | 1.1 (−.6 to 2.7) | 86 (18) | 9 (1–17) | 6 (−2 to 15) | −1.51 (1.37) | 0.68 (−.07 to 1.43) | 0.77 (−.06 to 1.59) |
| Not viremic (n = 109) | 14.7 (3.8) | P = .03 | P = .20 | 77 (18) | P = .03 | P = .16 | −2.19 (1.74) | P = .07 | P = .07 | |
| HCV treatment status | Prior HCV treatment history (n = 61) | 14.5 (3.5) | −0.5 (−2.0 to .9) | 0.3 (−1.1 to 1.7) | 75 (17) | −3 (−10 to 4) | 1 (−6 to 8) | −2.26 (1.65) | −0.16 (−.83 to .51) | 0.21 (−.53 to .96) |
| No prior HCV treatment history (n = 48) | 15.0 (4.1) | P = .46 | P = .41 | 78 (20) | P = .39 | P = .81 | −2.10 (1.87) | P = .63 | P = .58 | |
| Exposure to interferon and/or ribavirin | Exposed to interferon/ribavirin (n = 15) | 15.7 (4.2) | 1.6 (−.5 to 3.7) | 1.8 (−.4 to 4.0) | 82 (19) | 9 (−1 to 18) | 11 (−1 to 22) | −1.75 (2.04) | 0.67 (−.30 to 1.65) | 0.69 (−.43 to 1.82) |
| Not exposed to interferon/ribavirin (n = 46) | 14.1 (3.2) | P = .12 | P = .11 | 73 (16) | P = .09 | P = .07 | −2.43 (1.49) | P = .17 | P = .22 |
| Comparison . | Exposed Group . | DLCO (mL/min/mm Hg), Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differencea (95% CI) . | Percent Predicted DLCO, Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differenceb (95% CI) . | DLCO z Score, Mean (SD) . | Unadjusted Mean Difference (95% CI) . | Adjusted Mean Differenceb (95% CI) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Comparison Group . | ||||||||||
| HCV seropositivity | Seropositive (n = 133) | 15.1 (4.0) | −2.7 (−3.4 to −1.9) | −1.2 (−1.9 to −.4) | 78 (18) | −10 (−13 to −6) | −5 (−9 to −1) | −2.07 (1.70) | −0.78 (−1.07 to −.49) | −0.71 (−1.05 to −.37) |
| Seronegative (n = 536) | 17.7 (4.1) | P < .0001 | P = .004 | 88 (17) | P < .0001 | P = .01 | −1.29 (1.47) | P < .001 | P < .001 | |
| HCV viremia | Viremic (n = 24) | 16.6 (4.5) | 1.9 (.2–3.7) | 1.1 (−.6 to 2.7) | 86 (18) | 9 (1–17) | 6 (−2 to 15) | −1.51 (1.37) | 0.68 (−.07 to 1.43) | 0.77 (−.06 to 1.59) |
| Not viremic (n = 109) | 14.7 (3.8) | P = .03 | P = .20 | 77 (18) | P = .03 | P = .16 | −2.19 (1.74) | P = .07 | P = .07 | |
| HCV treatment status | Prior HCV treatment history (n = 61) | 14.5 (3.5) | −0.5 (−2.0 to .9) | 0.3 (−1.1 to 1.7) | 75 (17) | −3 (−10 to 4) | 1 (−6 to 8) | −2.26 (1.65) | −0.16 (−.83 to .51) | 0.21 (−.53 to .96) |
| No prior HCV treatment history (n = 48) | 15.0 (4.1) | P = .46 | P = .41 | 78 (20) | P = .39 | P = .81 | −2.10 (1.87) | P = .63 | P = .58 | |
| Exposure to interferon and/or ribavirin | Exposed to interferon/ribavirin (n = 15) | 15.7 (4.2) | 1.6 (−.5 to 3.7) | 1.8 (−.4 to 4.0) | 82 (19) | 9 (−1 to 18) | 11 (−1 to 22) | −1.75 (2.04) | 0.67 (−.30 to 1.65) | 0.69 (−.43 to 1.82) |
| Not exposed to interferon/ribavirin (n = 46) | 14.1 (3.2) | P = .12 | P = .11 | 73 (16) | P = .09 | P = .07 | −2.43 (1.49) | P = .17 | P = .22 |
Estimates for which the P value is less than 0.05 are in bold. Abbreviations: CI, confidence interval; DLCO, diffusing capacity for carbon monoxide; HCV, hepatitis C virus; SD, standard deviation.
aAdjusted for age, height, education level, hemoglobin, carboxyhemoglobin, human immunodeficiency virus (HIV) infection, self-reported cigarette smoking (measured in pack-years and current smoking status), and self-reported heroin, cocaine, and cannabis use.
bAdjusted for age, education level, HIV infection, self-reported cigarette smoking (measured in pack-years and current smoking status), and self-reported heroin, cocaine, and cannabis use.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
